In a report by Fotheringham et al. (2009), it has been shown that high amounts of pre-treatment RAD23B in myeloma and cutaneous T-cell lymphoma cells are predictive of a high sensitivity to HDAC inhibitors [31]. Here, RAD23B is linked to primary cutaneous T-cell non-Hodgkin lymphoma.